Context Therapeutics Inc. announced on April 9, 2025, that the first patient has been dosed in the Phase 1 clinical trial of CT-95. CT-95 is a mesothelin (MSLN) x CD3 T cell engaging (TCE) bispecific antibody designed to target mesothelin-expressing cancers.
This milestone marks Context's second active clinical trial, following the dosing of the first patient in the CTIM-76 trial earlier in 2025. The Phase 1 trial for CT-95 is an open-label, dose escalation and expansion study to evaluate the safety and efficacy in subjects with MSLN-expressing advanced solid tumors, including pancreatic, ovarian, lung, and mesothelioma cancers.
The dose escalation portion of the study is expected to enroll up to 30 patients. Context anticipates sharing initial data for the CT-95 Phase 1 trial in mid-2026, further advancing its clinical pipeline in T cell engaging bispecific antibody therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.